While you are correct in that the tech has been around for years it is only recently that there has been some evidence that it could get by the FDA on its own merits. Nasart was rightly or not going on the word of a now gone FDA official that all the “I”s and “t”s could be crossed with a label advisory. NOT. So, imho, the recent small set of data points reboots earlier optimism. We shall see.
I completely agree with the dodgy Mikah purchases to let ne Nasrat’s personal pockets, but the company was on the verge of bankruptcy. It was strapped for cash and Nasrat has done an ok job at building it back up and creating a potentially solid pipeline. It came at a significant cost of dilution along with piss poor execution and terrible communication, but at the end of the day I’m content with where the company sits for the near and mid-term. There is no long-term since if the tech does get the green light from the FDA, the company will quickly be acquired at a much higher premium than 0.11. :)